
-
Celldex Therapeutics, Inc. NasdaqCM:CLDX Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Location: Perryville III Building, Hampton, NJ, 08827, United States | Website: https://www.celldex.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
647.4M
Cash
673.3M
Avg Qtr Burn
-42.88M
Short % of Float
16.20%
Insider Ownership
0.32%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Barzolvolimab (CDX-0159) (KIT receptor) Details KIT/Mast cell diseases, Chronic spontaneous urticaria, Chronic urticaria | Phase 3 Data readout | |
Barzolvolimab (CDX-0159) Details Chronic inducible urticaria | Phase 3 Initiation | |
Barzolvolimab (CDX-0159) (KIT receptor) Details Prurigo nodularis, Skin disease/disorder | Phase 2 Data readout | |
Barzolvolimab (CDX-0159) (KIT receptor) Details Skin disease/disorder, Atopic dermatitis | Phase 2 Data readout | |
Barzolvolimab (CDX-0159) Details Eosinophilic esophagitis (EoE) | Phase 2 Data readout | |
CDX-585 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CDX-622 Details Inflammatory disease | Phase 1 Data readout | |
CDX-527 (and PD-L1 / CD27) Details Solid tumor/s, Cancer | Failed Discontinued | |
CDX-1140 (CD40 agonist) Details Solid tumor/s, Cancer, Diffuse large B cell lymphoma | Failed Discontinued |